The test was successfully trialled at Imperial College London last year, ahead of a major global commercial launch later this year and was recognised by Frost & Sullivan's global research organisation at its 2013 European Growth, Innovation & Leadership Awards Banquet held in London.
"The major factor driving growth in the skin care market is the high demand for anti-ageing products,” comments Vin Nee Lim, industry analyst for Frost & Sullivan.
“Frost & Sullivan recognises the innovation and commercial significance of geneOnyx's solution. In view of the potential of emerging molecular biology techniques and the increasing demand for preventive anti-ageing solutions, we expect that geneOnyx's product will have a significant impact on the cosmetic industry, enabling a fully end-to-end customer service."
"Genetic profiling and advanced analysis of the biochemical mechanisms of skin ageing is leading to the development of revolutionary new diagnostic tools that can provide specific prevention and treatment strategies to consumers,” adds Dr Martin Stow, Chief Operating Officer for geneOnyx.
“With this award, we are extremely pleased to be acknowledged by Frost & Sullivan as pioneers in the high-growth area of personalised cosmeceuticals."
The on-the-spot service works using a simple saliva sample test, which delivers extracted DNA to a computer microchip that simultaneously amplifies and detects genetic signatures in the DNA.
The DNA computer microchip is plugged into a cloud-connected gateway device linked to CosMos, geneOnyx's cloud-based analysis engine, and results are analysed to provide a personalised shortlist of specific geneOnyx skin care serums most appropriate and effective to the individual.
The differentiating factor is that samples do not need to be sent for lab testing to get results; they can be done on the spot, and ready within 30 minutes.